ArticleMolecular neurobiology2025
The Role of Toll-like Receptor 3 Signaling in Cognitive Impairment Induced by Propofol Addiction.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microglial Activation Is Associated with Hippocampal Synaptic Degeneration and Cognitive Deficits Following Repeated Propofol Exposure.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Growing preclinical and clinical evidence suggests that propofol has the potential for abuse and addiction. Clinical studies have investigated the association of propofol exposure with health, behavioral, and cognitive problems. Toll-like receptor 3 (TLR3) is a group of pattern recognition receptors in the innate immune system involved in the pathogenesis of psychiatric and neurological disorders, including neurodegeneration and drug abuse. However, whether TLR3 can be activated under propofol abuse conditions and contribute to the development of cognitive dysfunction has not been determined. Here, we demonstrated that propofol-induced attenuation of cognitive function and increased TLR3 expression in the hippocampus significantly enhanced neuroinflammation and impaired synapse formation in the hippocampus, ultimately leading to cognitive dysfunction. Mechanistically, the regulatory effects of TLR3 in propofol addiction were mediated by TLR3-mediated TRIF signaling. We further developed a propofol addiction model in TLR3 knockout mice and found that cognitive dysfunction and neuroinflammation were significantly reduced in TLR3 knockout mice. Thus, our results indicated that TLR3 contributes to propofol-induced cognitive impairment by enhancing neuroinflammation and impairing neuronal morphology in the hippocampus and might serve as a promising therapeutic target for the treatment of cognitive dysfunction caused by propofol abuse.
Indexed as
Identifiers
41381904What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.